Beruflich Dokumente
Kultur Dokumente
Page 1 of 11
Research
RESEARCH
Cardiovascular events after clarithromycin use in lower
respiratory tract infections: analysis of two prospective
cohort studies
OPEN ACCESS
1
Abstract
Objective To study the association of clarithromycin with cardiovascular
events in the setting of acute exacerbations of chronic obstructive
pulmonary disease and community acquired pneumonia.
Design Analysis of two prospectively collected datasets.
Setting Chronic obstructive pulmonary disease dataset including patients
admitted to one of 12 hospitals around the United Kingdom between
2009 and 2011; Edinburgh pneumonia study cohort including patients
admitted to NHS Lothian Hospitals between 2005 and 2009.
Population 1343 patients admitted to hospital with acute exacerbations
of chronic obstructive pulmonary disease and 1631 patients admitted
with community acquired pneumonia.
Main outcome measures Hazard ratios for cardiovascular events at
one year (defined as hospital admissions with acute coronary syndrome,
decompensated cardiac failure, serious arrhythmia, or sudden cardiac
death) and admissions for acute coronary syndrome (acute ST elevation
myocardial infarction, non-ST elevation myocardial infarction, and
unstable angina). Secondary outcomes were all cause and cardiovascular
mortality at one year.
Results 268 cardiovascular events occurred in the acute exacerbations
of chronic obstructive pulmonary disease cohort and 171 in the
community acquired pneumonia cohort over one year. After multivariable
adjustment, clarithromycin use in acute exacerbations of chronic
obstructive pulmonary disease was associated with an increased risk
of cardiovascular events and acute coronary syndromehazard ratios
1.50 (95% confidence interval 1.13 to 1.97) and 1.67 (1.04 to 2.68). After
multivariable adjustment, clarithromycin use in community acquired
Introduction
Acute exacerbations of chronic obstructive pulmonary disease
and community acquired pneumonia are two of the most
frequent causes of admission to hospital in the United Kingdom.1
Antibiotics, including clarithromycin, are commonly prescribed
during acute exacerbations of chronic obstructive pulmonary
disease, especially in the presence of increased breathlessness,
sputum volume, and purulence.2 However, their widespread use
Subscribe: http://www.bmj.com/subscribe
Page 2 of 11
RESEARCH
Methods
Study populations
This paper describes a secondary analysis of two large
prospectively collected datasets. These were a multicentre
observational study of patients admitted to hospital with
exacerbations of chronic obstructive pulmonary disease and the
Edinburgh pneumonia study cohort.
Subscribe: http://www.bmj.com/subscribe
Page 3 of 11
RESEARCH
Outcome
The primary outcome was the association between
clarithromycin use and the first hospital admission due to a
cardiovascular event or acute coronary syndrome (acute ST
elevation myocardial infarction, non-ST elevation myocardial
infarction, and unstable angina) within one year. Secondary
outcomes were cardiovascular mortality and all cause mortality
at one year.
Clarithromycin use
We classified all patients who received at least one dose of
clarithromycin during their hospital admission as macrolide
users. We compared them with patients who did not receive any
macrolide antibiotics during their admission.
Data analysis
We used SPSS version 21 for statistical analyses. For propensity
matching, we used the propensity matching add-on for SPSS
(SPSS essentials for R and R version 2.14.2).
Missing data
Sensitivity analysis
Page 4 of 11
RESEARCH
Results
The EXODUS dataset included 1343 patients, and the
community acquired pneumonia cohort had 1631 patients; table
1 shows their baseline characteristics. Severity measured by
BAP-65 differed significantly between clarithromycin users and
non-users in the chronic obstructive pulmonary disease cohort,
but other severity markers and demographics were similar.
Significant baseline disparities existed between clarithromycin
users and non-users in the community acquired pneumonia
cohort.
Page 5 of 11
RESEARCH
Missing data
In the chronic obstructive pulmonary disease cohort, missing
data accounted for less than 1% of the data. Complete datasets
with no missing data in any fields were available in 84.1% of
No commercial reuse: See rights and reprints http://www.bmj.com/permissions
Discussion
This is the first study showing that use of clarithromycin in the
context of exacerbations of chronic obstructive pulmonary
disease and community acquired pneumonia may be associated
with excess cardiovascular events that last beyond the period
of prescription. Clarithromycin is the most widely used
macrolide in the UK and is strongly recommended for use in
patients with severe community acquired pneumonia. Previous
studies have suggested an excess cardiovascular morbidity after
clarithromycin use,14 but these patients were selected on the
basis of pre-existing cardiovascular risk rather than having a
defined infective episode requiring treatment with this drug.
Other studies have shown a short term association seen only
during the time of administration.12 13 The observed association
with cardiovascular events is of a similar magnitude to that seen
in stable non-infected patients with established coronary artery
disease.14 Our data suggest that the increased risk may persist
beyond the time when clarithromycin is stopped.
Page 6 of 11
RESEARCH
Implications of findings
Evidence is accumulating for long term cardiovascular risks
associated with macrolides.14 15 The role of antibiotics in
exacerbations of chronic obstructive pulmonary disease is
controversial,3 4 and no evidence from controlled trials suggest
that macrolides are superior to the alternatives in this situation.
As this study is observational in nature, the findings need to be
validated in other datasets before recommendations to change
practice can be made.
Conclusion
The use of clarithromycin in the setting of hospital admissions
for infective exacerbations of chronic obstructive pulmonary
disease or community acquired pneumonia may be associated
with increased cardiovascular events. Our findings require
validation in independent datasets, especially from primary care
settings and through randomised controlled trials of macrolides
with long term follow-up.
We thank Ross Archibald, University of Dundee; Louise Peet, University
of Dundee; Charly Sengheiser, Doncaster Royal Infirmary; Duneesha
De Fonseka, Doncaster Royal Infirmary; Gillian B Fleming, Edinburgh
Royal Infirmary; Hazel Rooney, Perth Royal Infirmary; Duncan Mills,
Royal Infirmary of Edinburgh; Sarah Higgins, Doncaster Royal Infirmary;
John Corcoran, John Radcliffe Hospital, Oxford; Joseph Hodgson, NHS
Tayside; Martin K Smith, NHS Borders; and Mudher Al-Khairalla,
Doncaster Royal Infirmary for their help with data collection.
Contributors: All authors were involved in the design of the study,
analysis and interpretation of results, and preparation and revision of
the manuscript. All authors had full access to all of the data in the study
and can take responsibility for the integrity of the data and the accuracy
of the data analysis. JDC is the guarantor.
Funding: No specific funding.
Competing interests: All authors have completed the ICMJE uniform
disclosure form at www.icmje.org/coi_disclosure.pdf (available on
request from the corresponding author) and declare: no support from
any organisation for the submitted work; no financial relationships with
any organisations that might have an interest in the submitted work in
the previous three years; no other relationships or activities that could
appear to have influenced the submitted work.
Ethical approval: Routine collection of clinical data was approved by
local Caldicott guardians and the local research ethics committee, with
the requirement for informed consent waived (reference number
NR/0906AB1). Additional data collection was approved by the South
East Scotland research ethics committee (reference numbers S1104/15
and S1103/27).
Data sharing: No additional data available.
1
2
3
4
5
6
7
8
9
10
11
12
National Respiratory Training Centre. Impact of respiratory conditions: a guide for primary
care organisations. NRTC, 2002.
National Institute for Health and Clinical Excellence. Chronic obstructive pulmonary
disease: management of chronic obstructive pulmonary disease in adults in primary and
secondary care. NICE, 2010. (Clinical guideline 101.)
Monso E, Ruiz J, Rosell A, Manterola J, Fiz J, Morera J, et al. Bacterial infection in chronic
obstructive pulmonary disease: a study of stable and exacerbated outpatients using the
protected specimen brush. Am J Respir Crit Care Med 1995;152:1316-20.
White AJ, Gompertz S, Stockley RA. Chronic obstructive pulmonary disease. 6. The
aetiology of exacerbations of chronic obstructive pulmonary disease. Thorax
2003;58:73-80.
Restrepo MI, Mortensen EM, Waterer GW, Wunderink RG, Coalson JJ, Anzueto A. Impact
of macrolide therapy on mortality for patients with severe sepsis due to pneumonia. Eur
Respir J 2009;1:153-9.
Houck PM, MacLehose RF, Niederman MS, Lowery JK. Empiric antibiotic therapy and
mortality among medicare pneumonia inpatients in 10 western states: 1993, 1995, and
1997. Chest 2001;119:1420-6.
Lim WS, Baudouin SV, George RC, Hill AT, Jamieson C, Le Jeune I, et al. BTS guidelines
for the management of community acquired pneumonia in adults: update 2009. Thorax
2009;64:Siii1-55.
Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, et al.
Infectious Diseases Society of America/American Thoracic Society consensus guidelines
on the management of community-acquired pneumonia in adults. Clin Infect Dis
2007;44:S27-72.
Rodriguez A, Mendia A, Sirvent JM, Barcenilla F, de la Torre-Prados MV, Sol-Violn J,
et al. Combination antibiotic therapy improves survival in patients with community-acquired
pneumonia and shock. Crit Care Med 2007;35:1493-8.
Gupta S, Leatham EW, Carrington D, Mendall MA, Kaski JC, Camm AJ. Elevated C.
pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of MI.
Circulation 1997;96:404-7.
Gurfinkel E, Bozovich G, Daroca A, Beck E, Mautner B. Randomised trial of roxithromycin
in non-Q-wave coronary syndromes: ROXIS pilot study. Lancet 1997;350:404-7.
Ray WA, Murray KT, Meredith S, Narasimhulu SS, Hall K, Stein CM. Oral erythromycin
and the risk of sudden death from cardiac causes. N Engl J Med 2004;351:1089-96.
Subscribe: http://www.bmj.com/subscribe
Page 7 of 11
RESEARCH
16
17
18
19
20
21
22
23
Wayne RA, Murray KT, Hall K, Arbogast PG, Stein CM. Azithromycin and the risk of
cardiovascular death. N Engl J Med 2012;366:1881-90.
Jespersen CM, Als-Nielsen B, Damgaard M, Hansen JF, Hansen S, Hel OH, et al.
Randomised placebo controlled multicentre trial to assess short term clarithromycin for
patients with stable coronary heart disease: CLARICOR trial. BMJ 2006;332:22-7.
Gluud C, Als-Nielsen B, Damgaard M, Fischer Hansen J, Hansen S, Hel OH, et al.
Clarithromycin for 2 weeks for stable coronary heart disease: 6-year follow-up of the
CLARICOR randomized trial and updated meta-analysis of antibiotics for coronary heart
disease. Cardiology 2008;111:280-7.
Chalmers JD, Singanayagam A, Akram AR, Choudhury G, Mandal P, Hill AT. Safety and
efficacy of CURB65-guided antibiotic therapy in community-acquired pneumonia. J
Antimicrob Chemother 2011;66:416-23.
Chalmers JD, Singanayagam A, Murray MP, Hill AT. Prior statin use is associated with
improved outcomes in community-acquired pneumonia. Am J Med 2008;121:1002-7.
Shorr AF, Sun X, Johannes RS, Yaitanes A, Tabak YP. Validation of a novel risk score
for severity of illness in acute exacerbations of chronic obstructive pulmonary disease.
Chest 2011;140:1177-83.
Chalmers JD, Singanayagam A, Akram AR, Mandal P, Short PM, Choudhury G, et al.
Severity assessment tools for predicting mortality in hospitalised patients with
community-acquired pneumonia: systematic review and meta-analysis. Thorax
2010;65:878-83.
Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity
and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol
1982;5:649-55.
Sterne JA, White IR, Carlin JB, Spratt M, Royston P, Kenward MG, et al. Multiple imputation
for missing data in epidemiological and clinical research: potential and pitfalls. BMJ
2009;338:b2393.
Lvesque L, Hanley JA, Kezouh A, Suissa S. Problem of immortal time bias in cohort
studies: example using statins for preventing progression of diabetes. BMJ 2010;340:b508.
Hippisley-Cox J, Coupland C, Vinogradova Y, Robson J, Minhas R, Sheikh A, et al.
Predicting cardiovascular risk in England and Wales: prospective derivation and validation
of QRISK2. BMJ 2008;336:1475-82.
24
25
26
27
28
29
30
31
Altman DG, Bland JM. Interaction revisited: the difference between two estimates. BMJ
2003;326:219.
Winkel P, Hilden J, Fischer Hansen J, Hildebrandt P, Kastrup J, Kolmos HJ, et al. Excess
sudden cardiac deaths after short-term clarithromycin administration in the CLARICOR
trial: why is this so, and why are statins protective? Cardiology 2011;118:63-7.
Altman DG, Andersen PK. Calculating the number needed to treat for trials where the
outcome is time to an event. BMJ 1999;319:1492.
Bril F, Gonzalez CD, Di Girolamo G. Antimicrobial agents-associated with QT interval
prolongation. Curr Drug Saf 2010;5:85-92.
El Moussaoui R, de Borgie CA, van den Broek P, Hustinx WN, Bresser P, van den Berk
GE, et al. Effectiveness of discontinuing antibiotic treatment after three days versus eight
days in mild to moderate-severe community acquired pneumonia: randomised, double
blind study. BMJ 2006;332:1355-8.
Donaldson GC, Hurst JR, Smith CJ, Hubbard RB, Wedzicha JA. Increased risk of
myocardial infarction and stroke following exacerbation of COPD. Chest 2010:137:1091-7.
Singanayagam A, Singanayagam A, Elder DH, Chalmers JD. Is community-acquired
pneumonia an independent risk factor for cardiovascular disease? Eur Respir J
2012;39:187-96.
Albert RK, Connett J, Bailey WC, Casaburi R, Cooper JA Jr, Criner GJ, et al. Azithromycin
for prevention of exacerbations of COPD. N Engl J Med 2011;365:689-98.
Subscribe: http://www.bmj.com/subscribe
Page 8 of 11
RESEARCH
Tables
Table 1| Baseline characteristics. Values are numbers (percentages) unless stated otherwise
Characteristics
Study cohort
Clarithromycin user
COPD cohort
(n=1343)
(n=281)
(n=1062)
72 (63-79)
70 (63-79)
72 (63-80)
Male sex
655 (49)
134 (48)
521 (49)
Active smokers
448 (33)
90 (32)
358 (34)
377 (28)
72 (26)
305 (29)
Previous stroke
195 (15)
40 (14)
155 (15)
Renal failure
115 (9)
30 (11)
85 (8)
Diabetes
203 (15)
34 (12)
169 (16)
171 (13)
40 (14)
131 (12)
Non-clarithromycin user
122 (9)
21 (7)
101 (10)
46 (34-67)
45 (35-62)
47 (35-67)
4 (3-5)
4 (3-5)
4 (3-5)
218 (21)
265 (20)
47 (17)
CAP cohort
(n=1631)
(n=980)
(n=651)
66 (53-77)
65 (53-76)
68 (53-78)
Male sex
806 (49)
496 (51)
310 (48)
Active smokers
573 (35)
369 (38)
204 (31)
406 (25)
235 (24)
171 (26)
Previous stroke
166 (10)
94 (10)
72 (11)
Liver disease
83 (5)
53 (5)
30 (5)
Renal failure
72 (4)
48 (5)
24 (4)
Diabetes
152 (9)
107 (11)
45 (7)
727 (45)
489 (50)
238 (37)
BAP65=elevated blood urea, altered mental status, pulse >109, and age >65 years; CAP=community acquired pneumonia; COPD=chronic obstructive pulmonary
disease; FEV1=forced expiratory volume in one second; IQR=interquartile range; MRC=Medical Research Council; PSI=pneumonia severity index.
Subscribe: http://www.bmj.com/subscribe
Page 9 of 11
RESEARCH
Table 2| Frequency of cardiovascular events in patient cohorts. Values are numbers (percentages)
COPD cohort
CAP cohort
Clarithromycin user
(n=281)
Non-clarithromycin user
(n=1062)
Clarithromycin user
(n=980)
Non-clarithromycin user
(n=651)
73 (26.0)
195 (18.4)
123 (12.6)
48 (7.4)
Myocardial infarction
12 (4.3)
29 (2.7)
25 (2.6)
9 (1.4)
14 (5.0)
40 (3.8)
29 (3.0)
11 (1.7)
32 (11.4)
56 (5.3)
32 (3.3)
21 (3.2)
Arrhythmia
47 (16.7)
108 (10.2)
64 (6.5)
23 (3.5)
2 (0.7)
3 (0.3)
14 (1.4)
6 (0.9)
Events
Sum total of events may be greater than number of patients with events, as some patients had more than one cardiovascular event.
CAP=community acquired pneumonia; COPD=chronic obstructive pulmonary disease; NSTEMI=non-ST elevation myocardial infarction.
Subscribe: http://www.bmj.com/subscribe
Page 10 of 11
RESEARCH
COPD cohort
CAP cohort
1.00 (reference)
1.00 (reference)
Unadjusted
Adjusted
Unadjusted
Adjusted
Unadjusted
Adjusted
Unadjusted
Adjusted
No clarithromycin
<3 days:
3-6 days:
7 days:
>7 days:
Subscribe: http://www.bmj.com/subscribe
Page 11 of 11
RESEARCH
Figures
Fig 1 Cox adjusted survival curves for cardiovascular events in acute exacerbations of chronic obstructive pulmonary
disease cohort
Fig 2 Cox adjusted survival curves for cardiovascular events in community acquired pneumonia cohort
Subscribe: http://www.bmj.com/subscribe